38821-49-7
- Product Name：Carbidopa
- Molecular Formula：C10H16N2O5
- Purity：99%
- Molecular Weight：244.247
Product Details:
CasNo： 38821-49-7
Molecular Formula： C10H16N2O5
Buy Reliable Quality Carbidopa,Sale 38821-49-7 Safe Delivery
- Molecular Formula:C10H14N2O4*H2O
- Molecular Weight:244.247
- Vapor Pressure:5.27E-12mmHg at 25°C
- Boiling Point:528.7 °C at 760 mmHg
- Flash Point:273.5 °C
- PSA：125.04000
- Density:1.42 g/cm3
- LogP:0.97380
Carbidopa(Cas 38821-49-7) Usage
|
Chemical Properties |
white or yellowish-white powder. almost odorless. combined with levodopa for Parkinson's disease and Parkinson's syndrome. |
|
Description |
Carbidopa is a medication primarily used in the management and treatment of Parkinson's disease (PD). It belongs to the class of drugs known as decarboxylase inhibitors. When combined with levodopa, carbidopa is integral in the treatment of Parkinson's disease, often referred to as shaking palsy or paralysis agitans. Parkinson's disease is a disorder affecting the central nervous system, which includes the brain and spinal cord. |
|
Uses |
Carbidopa/levodopa therapy may interact with high-protein diets. Since protein may interfere with the absorption of levodopa, it is generally recommended to avoid high-protein meals when taking carbidopa/levodopa. Protein intake should be spaced evenly throughout the day or as directed by a healthcare professional. Carbidopa/levodopa combination therapy was commercially available in 1975 after the advantages of adding a dopa decarboxylase inhibitor to treatment were discovered. The combination was found to reduce side effects and provide better symptom control for Parkinson's disease patients. |
|
Brand name |
Lodosyn (Bristol-Myers Squibb). |
|
Therapeutic Function |
Muscle relaxant, Antiparkinsonian |
InChI:InChI=1/C10H14N2O4.H2O/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6;/h2-4,12-14H,5,11H2,1H3,(H,15,16);1H2
38821-49-7 Relevant articles
Asymmetric Synthesis of L-carbidopa based on a highly enantioselective α-amination
Pericas, Lex,Shafir, Alexandr,Vallribera, Adelina
supporting information, p. 1448 - 1451 (2013/06/27)
A stereoselective synthesis of l-carbido...
Levodopa with benserazide or carbidopa in Parkinson disease
U. K. Rinne, M.D., and P. Mölsä, M.D.
, Neurology,December 1979 issue 29 (12) 1584-1589
In pretrial studies of plasma levodopa responses, 200 mg of levodopa and 50 mg of benserazide was equal to 250 mg of levodopa combined with 25 mg of carbidopa. Equal plasma levodopa responses to both combinations were also found during the trial.
The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: The mechanism of action in the treatment of parkinsonism
Dr. John G. Nutt MD, William R. Woodward PhD, John L. Anderson MS
, Annals of neurology, Volume18, Issue5 November 1985 Pages 537-543
Carbidopa reduced by 50% both the infusion rate required to produce a clinical response and the time required for plasma clearance of levodopa. Using this value for clearance, it is estimated that carbidopa doubles the bioavailability of orally administered levodopa.
38821-49-7 Upstream products
-
37178-37-3
L-DOPA ethyl ester
-
1426847-87-1
(S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrobromide
Relevant Products
-
ApixabanCAS：503612-47-3
-
Ondansetron HclCAS：103639-04-9
-
Methyl Prednisolone AcetateCAS：53-36-1
